The additional benefits of improved glycemic control and reduced cardiovascular risk further position SGLT-2 inhibitors as a promising therapeutic avenue for addressing the complex metabolic disturbances associated with MetS (289). The gene discussed is SLC5A2; the disease is metabolic syndrome.